BIO Asia–Taiwan 2021 亞洲生技大會

BIO Asia–Taiwan 2021 亞洲生技大會


Paula Pohja-Hutchison

Session 5 – Pandemic Control after Vaccination (A)

Date:22 July (Thursday)
Time:  09:00 – 10:30 (GMT+8)

Paula Pohja-Hutchison

Global Policy Director, COVID-19 Vaccine

Paula Pohja-Hutchison is the Global Policy Director for AstraZeneca’s COVID-19 vaccine. Before working on the COVID-19 vaccine programme she supported the company’s Cardiovascular, Renal and Metabolism Therapy Area.
Prior to joining AstraZeneca’s Global team in 2017, Paula worked in the European Parliament in Brussels, the Foreign Office and in consultancy in London. She has more than 15 years of experience in the healthcare industry and working in public policy. 

Speech title & Synopsis

Developing a Vaccine in Extraordinary Times

Since early 2020 when the true scale of the crisis became clear, AstraZeneca has committed to help defeat COVID-19. Recognising the urgent need for a vaccine to defeat the virus, we joined forces with the University of Oxford, bringing together its world-class expertise in vaccinology with our global development and manufacturing capabilities.
We have accelerated clinical development and rapidly mobilised partnerships and a global supply chain that support a broad, timely and equitable supply of a vaccine around the world, and at no profit during the pandemic.
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal & Metabolism, and Respiratory & Immunology. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.